asthma
ASTHMA
Asthma is a chronic inflammatory disease of the airways in the lungs of children and adults.
The patient usually complains of shortness of breath, chest tightness and coughing with wheezing.
Goals of treatment are effective symptom control with minimal or no exacerbations, minimal or no nocturnal and daytime symptoms, no limitations on activities, minimal or no need for reliever treatment, and minimal adverse effects of medication.

Definition

  • Defined as a heterogeneous disease characterized by chronic airway inflammation that results in recurrent episodes of wheeze, shortness of breath (SOB), chest tightness &/or cough that vary over time & in intensity, with variable expiratory airflow limitation

Signs and Symptoms

  • Symptoms are usually associated with airflow obstruction; which is often reversible either spontaneously or with treatment
  • These symptoms tend to be intermittent, variable, worse at night or upon waking, & provoked by triggers, eg exercise, allergens, weather changes, viral infections

Risk Factors

  • Asthma phenotypes (clusters of asthma characteristics) differ in clinical manifestations, pathophysiology & demographic location of the patient
    • Allergic asthma: present in childhood, with a positive family history of asthma, & previous history of allergy such as eczema, food allergy, allergic rhinitis, etc
    • Non-allergic asthma: also called adult-onset; asthma presenting & diagnosed for the 1st time in adult years
    • Asthma with fixed airflow limitation: airway wall remodeling due to chronic airway inflammation causing irreversible airflow obstruction
    • Asthma with obesity: prevalence of symptomatic asthma is increased in those suffering from obesity
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Jun 2017
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Jairia Dela Cruz, 21 Jun 2017
Control treatment with montelukast may effectively reduce acute exacerbations in preschool children with mild persistent asthma, according to a study from Japan.
Tristan Manalac, 27 Jun 2017
Prolonged sleep duration is an independent predictor of higher incident atrial fibrillation (AF) risks in a Chinese population, reports a new prospective, population-based study.
Rachel Soon, 01 Jun 2017

Pirfenidone, an oral antifibrotic and anti-inflammatory agent, is now indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in Malaysia.